跳至主要内容
临床试验/NL-OMON54344
NL-OMON54344招募中不适用

Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine - PRECISER

niversitair Medisch Centrum Groningen0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Ageover 18 years
  • - Clinical indication for ECT (as indicated by the treating
  • physician/psychiatrist)
  • - Depressive disorder (as assessed by the treating psychiatrist)
  • - Dutch as first language

排除标准

  • - Currently using rivastigmine, galantamine, donezepil (all cholinesterase
  • inhibitors for mild to moderate Alzheimer*s Disease).
  • - Pregnancy and/or lactation/breast feeding
  • - Suspicion of neurodegenerative disorders (as diagnosed earlier)
  • - Contraindications for ECT (recent myocardinfarct, recent cerebrovasculair
  • accident, recent intracranial surgery, pheochromocytoma and instable angina
  • - Contraindications for rivastigmine (bradycardia or atrioventricular (AV)
  • conduction disorders (first degree AV-block excluded))
  • - Patients who have had an allergic reaction to rivastigmine
  • - Cognitive disorder not explained by the depressive episode
  • - If receiving outpatient ECT treatment, having no person available to
  • apply the rivastigmine/non-active patch

研究者

相似试验